Balance Sheet
Cash Flow Statement
Amortization of GoodwillAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Cash from Investing Activities: 2018-2024

Historic Cash from Investing Activities for Legend Biotech (LEGN) over the last 7 years, with Dec 2024 value amounting to -$850.5 million.

  • Legend Biotech's Cash from Investing Activities fell 106.08% to -$20.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$16.7 million, marking a year-over-year increase of 95.29%. This contributed to the annual value of -$850.5 million for FY2024, which is 1016.67% down from last year.
  • Legend Biotech's Cash from Investing Activities amounted to -$850.5 million in FY2024, which was down 1,016.67% from $92.8 million recorded in FY2023.
  • Legend Biotech's 5-year Cash from Investing Activities high stood at $92.8 million for FY2023, and its period low was -$850.5 million during FY2024.
  • Moreover, its 3-year median value for Cash from Investing Activities was -$77.1 million (2022), whereas its average is -$278.3 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first soared by 220.36% in 2023, then tumbled by 1,016.67% in 2024.
  • Legend Biotech's Cash from Investing Activities (Yearly) stood at -$24.2 million in 2020, then tumbled by 706.75% to -$195.0 million in 2021, then skyrocketed by 60.46% to -$77.1 million in 2022, then surged by 220.36% to $92.8 million in 2023, then crashed by 1,016.67% to -$850.5 million in 2024.